By Bernard P Wolfsdorf, Joseph M Barnett and Robert J Blanco of Wolfsdorf Rosenthal About a decade ago Thomas L Friedman, foreign affairs columnist for The New York Times, published The World is Flat: A Brief History of the Twenty-First Century, which described the complexities of 21st century globalisation to demonstrate a growing “levelling” of the global economy.
By Laura Devine of Laura Devine Solicitors First announced in the Queen’s Speech in May 2015, the UK’s newest Immigration Bill tackles a broad spectrum of issues and builds on the Immigration Act 2014, which in part sought to create a “hostile environment” for undocumented migrants in the UK. For businesses and individuals alike, the proposed measures could have significant effects.
By Maria Jockel of Holding Redlich Following the merger of the Department of Immigration and Border Protection (the Department) with the Australian Customs and Border Protection Service, and the establishment of the Australian Border Force as its operational enforcement arm, the Department is now an enforcement agency (and a criminal enforcement agency).
By Peter J Pliszka of Fasken Martineau DuMoulin During the relatively short history of class proceedings in Canada, developers and manufacturers of medical devices and pharmaceuticals (medical products) have found themselves at the receiving end of a significant number of class action claims. To date, the main battleground in respect of these claims has been the certification motion, a preliminary step in which the court assesses whether or not a given claim should proceed as a class action.
By Josefine Sommer and Maurits Lugard of Sidley Austin Medical devices manufacturers are braced for the overhaul of the EU Medical Devices Directives. New Regulations, which are closer to final adoption than ever (although not quite there yet), are expected to clarify the regulation of medical devices in Europe – at least once the delegated and implementing acts have been put in place.
By Manuel Lobato and Marco Yago of Bird & Bird This article intends to briefly describe two elements of indirect infringement of pharmaceutical patents that have been discussed in Spanish Courts, namely, products with a skinny label and the principle of territoriality in the article 51.1 Spanish Patent Act.
By Nicola Dagg of Allen & Overy The requirement that a patent specification must disclose the invention in a manner that is “clear enough and complete enough for it to be performed by a person skilled in the art” (UK Patents Act/EPC) represents a significant source of commercial uncertainty for patentees.
It is not possible to buy entry into any Who's Who Legal publication
Nominees have been selected based upon comprehensive, independent survey work with both general counsel and private practice lawyers worldwide. Only specialists who have met independent international research criteria are listed.